NICE technology appraisals
This article was originally published in The Gray Sheet
Executive Summary
Coronary artery stents, implantable cardioverter defibrillators, and hip prostheses will be evaluated this fall by the National Institute For Clinical Excellence, a technology appraisal program for the National Health Service in the U.K. (1"The Gray Sheet" March 22, p. 12). Manufacturers of the selected products are expected to submit existing data on clinical and cost effectiveness, the group explains Aug. 6. NICE will issue a guidance on each manufacturer's technology, indicating "whether, and under what circumstances, the technology should be routinely used in the NHS" and "whether its use should be restricted to certain categories of patients." Other areas to be examined include cervical screening, inhaler systems, hearing aids, laparoscopic surgery, and wound care
You may also be interested in...
U.K. To Begin Clinical, Cost-Effectiveness Device Assessments Next Month
Britain's National Institute of Clinical Excellence (NICE) plans to conduct on an annual basis clinical and cost-effectiveness evaluations of between 30 and 50 new and existing medical technologies, Edward Hutt, division director Quintiles Medical Technology Consultants, said March 14.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.